NYSE
OrganizationRelationship Network
HOUSE_OVERSIGHT_026578.jpg
This document is page 7 of a 'Global Asset Allocation' report by J.P. Morgan, dated November 9, 2012. It contains standard legal disclosures regarding analyst certification, compensation, options research, and a detailed list of J.P. Morgan's legal entities and regulatory bodies across various international jurisdictions (US, UK, Asia, Middle East, etc.). The document bears the Bates stamp 'HOUSE_OVERSIGHT_026578', indicating it was produced as part of a House Oversight Committee investigation, likely related to J.P. Morgan's internal records.
HOUSE_OVERSIGHT_024649.jpg
This document is page 13 of an Executive Summary from a 2017 Ackrell Capital investment report regarding the cannabis industry. It discusses the increase in strategic investor activity, citing investments by Constellation Brands and Scotts Miracle-Gro, while noting a continuing funding gap due to a lack of institutional support. The document outlines the investment outlook, noting that while billions were raised in 2017, most companies are in early development stages with revenues under $5 million. The document bears a 'HOUSE_OVERSIGHT_024649' stamp, suggesting it is part of a larger document production to the House Oversight Committee.
HOUSE_OVERSIGHT_025584.jpg
This document is a boilerplate disclaimer and disclosure page from a Morgan Stanley research report (page 34), stamped with a House Oversight Bates number (HOUSE_OVERSIGHT_025584). It details Morgan Stanley's stock rating system (Overweight, Equal-weight, etc.), provides a statistical distribution of their stock ratings as of December 31, 2017, and defines analyst industry views. While the document is part of a batch likely related to the House Oversight investigation (potentially regarding Epstein/financial records), this specific page contains no specific information regarding Jeffrey Epstein, his associates, or specific transactions.
HOUSE_OVERSIGHT_025227.jpg
This document is a market commentary by Michael Cembalest, Chief Investment Officer at J.P. Morgan, discussing the state of financial markets, economic challenges, and investment strategies in 2011. It highlights issues like European sovereign risk, weak labor compensation, political divides, and inflation risks, emphasizing the importance of realistic market assessment and identifying opportunities amid economic difficulties, while also providing disclaimers about the nature of the commentary and J.P. Morgan's services.
HOUSE_OVERSIGHT_025220.jpg
This document is a general market commentary and disclaimer from J.P. Morgan Chase & Co. and its affiliates, dated 2011. It outlines the nature of the information provided, investment risks, and disclaims tax advice, concluding with a confidentiality notice for the email and a link to full disclosures.
HOUSE_OVERSIGHT_024918.jpg
This document is a disclosure and disclaimer page from a Cowen Collaborative Insights equity research report dated February 25, 2019. It outlines Cowen's rating definitions (Outperform, Market Perform, Underperform), provides a statistical distribution of their ratings as of December 31, 2018, and lists legal notices for US, UK, and EU investors. The document bears a House Oversight Committee Bates stamp (HOUSE_OVERSIGHT_024918) and is watermarked for recipient Michael Cella.
HOUSE_OVERSIGHT_024762.jpg
This document is page 126 from a December 2017 Cannabis Investment Report by Ackrell Capital. It features a detailed comparison table of U.S. stock markets (Nasdaq, NYSE, and OTC), analyzing them by tiers, listed companies, market value, and regulatory requirements. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024762', indicating it was obtained during a House Oversight Committee investigation, likely related to financial records involving major banks or investment firms.
HOUSE_OVERSIGHT_024759.jpg
This document is page 123 of a report by Ackrell Capital regarding capital markets for cannabis companies, bearing a House Oversight Bates stamp. It presents statistical data on capital raised by U.S. publicly traded cannabis companies for the twelve months ending September 30, 2017, breaking down amounts by exchange (Nasdaq, NYSE, OTC). While part of a document production likely related to broader financial investigations (possibly involving banks linked to Epstein), this specific page contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024758.jpg
This document is page 122 of a December 2017 Cannabis Investment Report by Ackrell Capital. It provides a financial summary and stock price performance analysis of U.S. publicly traded cannabis-related companies as of November 2017. The report notes that the election of Donald Trump and the confirmation of Jeff Sessions did not negatively impact the stock performance of these companies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production to Congress.
HOUSE_OVERSIGHT_024757.jpg
This page from an Ackrell Capital report details capital raised by publicly traded cannabis companies for the year ending September 30, 2017, highlighting that Canadian companies raised significantly more capital than those in the U.S. or Australia. It also provides an overview of the U.S. public capital markets for cannabis, noting that while a few trade on major exchanges like Nasdaq and NYSE, the vast majority are "penny" stocks on the OTC market characterized by high risk and regulatory scrutiny from the SEC and FINRA.
HOUSE_OVERSIGHT_024755.jpg
This document is page 119 of a report by Ackrell Capital titled 'Capital Markets for Cannabis Companies.' It analyzes listing requirements for cannabis companies on US, Canadian, and Australian stock exchanges (NYSE, Nasdaq, OTC, TSX, CSE, ASX). It includes a statistical table summarizing market values, enterprise values, and revenue averages for cannabis-related companies as of November 30, 2017. The document bears a House Oversight Committee stamp.
HOUSE_OVERSIGHT_024754.jpg
This document is page 118 of a Cannabis Investment Report authored by Ackrell Capital in December 2017. It analyzes public capital markets, detailing strategic investments by major corporations like Constellation Brands and Scotts Miracle-Gro into the cannabis sector, and discusses market valuations and regulatory landscapes in the US, Canada, and abroad. The document bears a House Oversight stamp (024754), indicating it was likely gathered as evidence in a congressional investigation, though Jeffrey Epstein is not mentioned on this specific page.
HOUSE_OVERSIGHT_024201.jpg
This document is page 8 of a J.P. Morgan 'Eye on the Market' report dated October 22, 2012, containing standard legal disclaimers and regulatory disclosures for various international jurisdictions including the UK, Hong Kong, Singapore, and Latin America. It identifies Michael Cembalest as the source of opinions within the report and outlines limitations regarding tax advice and FDIC insurance. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was produced as part of a congressional investigation, likely related to the Epstein inquiry involving J.P. Morgan.
HOUSE_OVERSIGHT_025892.jpg
This document is an informational sheet or press release regarding the pharmaceutical product PRALUENT (alirocumab) manufactured by Sanofi. It details the ODYSSEY Phase 3 clinical trial program, safety information, and side effects. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, likely related to pharmaceutical lobbying or healthcare inquiries found within the broader dataset.
HOUSE_OVERSIGHT_018394.jpg
This document page, stamped HOUSE_OVERSIGHT_018394, appears to be an excerpt from a book or article discussing network theory, specifically 'Metcalfe's Law' and the power dynamics of technology platforms like Google. It details the history of Ethernet created by Bob Metcalfe in the 1970s and discusses the dangers of exclusion from critical networks, citing a 2011 paper by Rahul Tongia and Ernest J. Wilson III. While part of a House Oversight production likely related to broader investigations, this specific page focuses on theoretical concepts of network growth and exclusion costs without directly mentioning Jeffrey Epstein.
HOUSE_OVERSIGHT_018369.jpg
This document is page 137 of a manuscript or book, likely 'The Seventh Sense' (based on the specific terminology used in the text). It discusses the difference between physical geography and network topology, referencing a 1965 paper by Janelle and using Napoleon as an analogy for understanding new strategic dimensions. The page bears the Bates stamp HOUSE_OVERSIGHT_018369, indicating it was part of a document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_026366.jpg
This document is a corporate communication and product information sheet for the prescription drug Praluent (alirocumab), manufactured by Sanofi. It details the ODYSSEY clinical trial program, provides important safety information for patients, and includes a legal disclaimer. The document is marked with the identifier 'HOUSE_OVERSIGHT_026366' but contains no information whatsoever related to Jeffrey Epstein, his associates, finances, or travel.
HOUSE_OVERSIGHT_022358.jpg
This document is a standard financial disclaimer page from a JPMorgan Chase & Co. publication dated 2012. It details the risks of various investment products, states that the firm does not provide tax advice, and provides contact information for prospectuses. The Bates stamp 'HOUSE_OVERSIGHT_022358' indicates this page was included in materials for an investigation by the U.S. House of Representatives Committee on Oversight, which is its primary relevance to the Epstein case document trove.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity